<unk>  is an monoclonal antibody that is FDA approved for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V400 mutation positive, a BRAF inhibitor.   Common adverse reactions include pruritus, rash, constipation, decrease in appetite, diarrhea, nausea, arthralgia, cough, fatigue, erythroderma, adrenal insufficiency, hypophysitis, anemia,  hemolytic anemia, pneumonitis.
Pembrolizumab
Nivolumab
Afatinib
Ipilimumab
Acalabrutinib
Axitinib
Ruxolitinib
Neratinib